Small Interfering RNA Market Size

Small Interfering RNA Market size was valued at USD 14.97 billion in 2024 and is likely to cross USD 117.84 billion by 2037, expanding at more than 17.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of small interfering RNA is estimated at USD 17.03 billion.

The reason behind the growth is impelled by rising cases of cancer across the globe. Small interfering RNA has been studied as an effective treatment for cancer as it targets specific mRNA and blocks abnormal gene expression that causes the disease. By 2040, there will be more than 26 million new instances of cancer worldwide.

The growing partnerships and collaborations are believed to fuel the market growth. For instance, in 2022 Alnylam Pharmaceuticals and Novartis came together to treat liver disease by using siRNA to suppress a Novartis-discovered target, which could lead to the regeneration of functional liver cells and advance the possibility for new drugs in a variety of illness conditions.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of small interfering RNA is estimated at USD 17.03 billion.

The small interfering RNA market size was valued at USD 14.97 billion in 2024 and is likely to cross USD 117.84 billion by 2037, expanding at more than 17.2% CAGR during the forecast period i.e., between 2025-2037. Rising cases of cancer across the globe and the growing partnerships and collaborations will drive the market growth.

North America industry is likely to account for largest revenue share of 37% by 2037, impelled by increasing spending in healthcare in the region.

The major players in the market include GE, Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health, Agios Pharmaceuticals, Inc., Novartis

Small Interfering RNA Market Size